Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 2/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16559744 | 0.89 | OTUD7B (0.36) | CYP2D6OTUD7BALDH1A1MAPTOPRM1 | |
| SCHEMBL7880708 | 0.83 | OTUD7B (0.47) | CYP2D6OTUD7B | |
| SCHEMBL18559582 | 0.82 | OPRM1 (0.33) | OTUD7BKDM4ELMNAOPRM1OPRD1 | |
| SCHEMBL21370455 | 0.80 | OPRM1 (0.34) | OTUD7BALDH1A1KDM4EOPRM1OPRD1 | |
| SCHEMBL9963244 | 0.80 | OTUD7B (0.38) | CYP2D6OTUD7BALDH1A1MAPTKDM4E | |
| SCHEMBL16559745 | 0.80 | SMN1; SMN2 (0.38) | ALDH1A1MAPTTOP2ATOP2BTDP1 | |
| SCHEMBL18842877 | 0.80 | OPRD1 (0.36) | ALDH1A1KDM4ELMNAOPRM1OPRD1 | |
| SCHEMBL10062592 | 0.78 | CHRM2 (0.42) | OTUD7BKDM4EPDCD1LG2CD274 | |
| SCHEMBL22460223 | 0.77 | OPRM1 (0.38) | OPRM1OPRD1OPRK1OPRL1PDCD1LG2 | |
| SCHEMBL18592722 | 0.77 | OTUD7B (0.53) | CYP2D6OTUD7BTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | OXFORD FINANCE LLC | 2021-12-09 | — | — | US | disclosed |
| US-10954244-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2020-09-24 | — | — | US | disclosed |
| US-10723719-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | KALA BIO, Inc. | 2020-05-21 | — | — | US | disclosed |
| US-10544151-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2019-09-19 | — | — | US | disclosed |
| US-10351570-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-9802922-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802922-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2017-05-11 | — | — | US | disclosed |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2017-05-11 | — | — | US | disclosed |
| US-9580421-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580421-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-9212145-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | CYP2D6 3454/4885OTUD7B 877/4885ALDH1A1 1432/4885 |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | CYP2D6 3557/4885OTUD7B 1523/4885ALDH1A1 1517/4885 |
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | CYP2D6 3454/4885OTUD7B 877/4885ALDH1A1 1432/4885 |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | CYP2D6 3557/4885OTUD7B 1523/4885ALDH1A1 1517/4885 |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | CYP2D6 3557/4885OTUD7B 1523/4885ALDH1A1 1517/4885 |
| US-10544151-B2 | Compounds and uses thereof | RB1, VEGFA, KDR | CYP2D6 3620/4885OTUD7B 1358/4885ALDH1A1 1409/4885 |
| US-10954244-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | CYP2D6 3714/4885OTUD7B 1607/4885ALDH1A1 1477/4885 |
| US-10723719-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | CYP2D6 3454/4885OTUD7B 877/4885ALDH1A1 1432/4885 |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | CYP2D6 3454/4885OTUD7B 877/4885ALDH1A1 1432/4885 |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | CYP2D6 3454/4885OTUD7B 877/4885ALDH1A1 1432/4885 |
| US-10351570-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | CYP2D6 3714/4885OTUD7B 1607/4885ALDH1A1 1477/4885 |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | CYP2D6 3454/4885OTUD7B 877/4885ALDH1A1 1432/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | CYP2D6 2836/4885OTUD7B 143/4885ALDH1A1 3208/4885 |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | CYP2D6 3454/4885OTUD7B 877/4885ALDH1A1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.